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ABSTRACT 29 
Cefepime-enmetazobactam is a novel ß-lactam- ß-lactamase inhibitor combination with 30 
broad spectrum antimicrobial activity against a range of multi-drug resistant 31 
Enterobacteriaceae.  This agent is being developed for a range of serious hospital infections.  32 
An understanding of the extent of partitioning of both ß-lactam- ß-lactamase inhibitor into 33 
the human lung is required to better understand the potential role of cefepime-34 
enmetazobactam for the treatment of nosocomial pneumonia.  A total of 20 healthy 35 
volunteers were used to study the intrapulmonary pharmacokinetics of a regimen of 36 
cefepime-enmetazobactam 2g/1g q8h i.v.  Each volunteer contributed multiple plasma 37 
samples and a single epithelial lining fluid (ELF) sample obtained by bronchoalveolar lavage.  38 
Concentrations of cefepime and enmetazobactam were quantified using LC-MS/MS.  The 39 
pharmacokinetic data was modelled using a population methodology and Monte Carlo 40 
simulations were performed to assess the attainment of pharmacodynamic targets defined in 41 
preclinical models.  The concentration-time profiles of both agents in plasma and ELF were 42 
similar.  The mean ± standard deviation percentage partitioning of total drug concentrations 43 
of cefepime and enmetazobactam between plasma and ELF was 60.59 ± 28.62 and 53.03 ± 44 
21.05 %, respectively.  Using pharmacodynamic targets of cefepime >MIC and free 45 
enmetazobactam concentrations >2 mg/L in ELF of 20% of the dosing interval, a regimen of 46 
cefepime-enmetazobactam 2 grams/0.5 grams q8h i.v. infused over 2 hours resulted in a 47 
probability of target attainment of ≥90% for Enterobacteriaceae with cefepime-48 
enmetazobactam MICs ≤8 mg/L.  This result provides a rationale to further consider 49 
cefepime-enmetazobactam for the treatment of nosocomial pneumonia caused by multidrug 50 
resistant Enterobacteriaceae.  51 
 4 
INTRODUCTION 52 
 Cefepime-enmetazobactam is a new ß-lactam-ß-lactamase inhibitor combination with 53 
broad-spectrum activity against multi-drug resistant Enterobacteriaceae.  Enmetazobactam 54 
has potent activity against extended spectrum ß-lactamases (ESBLs) (1) and cefepime is 55 
stable against hydrolysis by OXA-48 and AmpC ß-lactamases (2).  Together, this combination 56 
has demonstrated potent activity against Enterobacteriaceae expressing ESBLs, OXA-48, 57 
and/or AmpC (1, 3).  Carbapenems are frequently used as the agent of choice for the 58 
treatment of ESBL producing Enterobacteriaceae and have recently been demonstrated to be 59 
superior to piperacillin-tazobactam in terms of 28-day mortality in patients with bacteremia 60 
(4).  ESBL-producing Enterobacteriaceae account for 31% of culture positive cases of 61 
nosocomial pneumonia in a recent clinical study (5).  The carbapenems are agents of last 62 
resort and are therefore a critically important resource for healthcare systems throughout 63 
the world.  New agents that can be used as carbapenem-sparing strategies are urgently 64 
required (6).  65 
Cefepime-enmetazobactam has recently completed a pivotal trial in patients with 66 
complicated urinary tract infection (cUTI; https://clinicaltrials.gov/ct2/show/NCT03687255; 67 
accessed 18th June 2020). In this ALLIUM Phase III trial, cefepime-enmetazobactam 68 
demonstrated superiority over piperacillin-tazobactam at the primary efficacy endpoint 69 
defined as clinical cure and microbiological eradication at test-of-cure in the mMITT 70 
population (7).   71 
 Nosocomial pneumonia is a common and frequently lethal disease with a crude 72 
mortality rate of 25-50%.  The 28-day mortality in a recent Phase III clinical trial comparing 73 
ceftolozane-tazobactam and meropenem was 24 and 25.3%, respectively (5).  The clinical 74 
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response after the completion of therapy is approximately 50% (5).  Suboptimal clinical 75 
outcomes are driven by underlying critical illness, relatively more resistant invasive 76 
pathogens, greater overall pharmacokinetic variability and high variability of partitioning of 77 
drug to the effect site (8).  Furthermore, for some agents, such as daptomycin, there may be 78 
idiosyncrasies of activity in the lung that render those agents less effective for the treatment 79 
of pneumonia (9).  Hence, specific preclinical and clinical studies are required to establish the 80 
efficacy and regimen that is likely to be effective for patients (8). 81 
 Assessment of drug partitioning into epithelial lining fluid of the human lung along 82 
with a compelling PK-PD rationale is a critical step for developing new antibiotics for 83 
pneumonia (10).  This was the basis for the initial approval of ceftazidime-avibactam for the 84 
treatment hospital-acquired pneumonia (HAP) including ventilator associated pneumonia 85 
(VAP) prior to completion of Phase III trial for this indication (11).  Meropenem-vaborbactam 86 
was approved by EMA for use in HAP including VAP based on a statistically powered Phase III  87 
trial patients with cUTI including pyelonephritis and a smaller open-label trial which included 88 
patients with HAP/VAP (https://www.ema.europa.eu/en/documents/product-89 
information/vaborem-epar-product-information_en.pdf; accessed 25th June 2020).   90 
Preclinical PK-PD studies in the thigh and lung model have been recently published for 91 
cefepime-enmetazobactam (12, 13).  In the latter, pharmacodynamic targets in plasma and 92 
ELF that resulted in various orders of logarithmic killing in the lung were determined (13).  93 
The primary purpose of this study was to estimate the extent of partitioning of cefepime-94 
enmetazobactam into ELF in healthy volunteers to help identify a regimen for nosocomial 95 




Demographics and Volunteer Details 99 
The demographics of the 20 volunteers enrolled in this study are summarized in Table 100 
1.  One volunteer (female, 23 years, 60.6 kg, BMI 20.7 kg/m2) could not tolerate 101 
bronchoscopy and was therefore excluded from the study.  A total of 19 volunteers with 102 
complete plasma PK and ELF samples were available for analysis and the development of a 103 
population PK model.  However, all 20 volunteers were included for reporting of safety. 104 
 105 
Safety of Cefepime-Enmetazobactam 106 
Cefepime-enmetazobactam was well tolerated.  There were no serious adverse 107 
events (SAE).  None of the treatment emergent adverse events (TEAEs) led to discontinuation 108 
of study drugs.  All adverse events spontaneously resolved without sequelae.   109 
A total of 59 adverse events were reported in 18 (90%) volunteers.  Of these 59 110 
adverse events, 57 events were reported in 18 (90%) volunteers were TEAEs, and 20 111 
reported in 8 (40%) volunteers were TEAEs that were judged to be causally related to the 112 
study drug.  None of the TEAEs were of severe intensity.  A total of 54 TEAEs were mild.  A 113 
total of 3 TEAEs reported in 2 (10%) volunteers (1 case of increased blood pressure reported 114 
by one volunteer, 1 case of hypotension and 1 case of presyncope reported by another 115 
volunteer) were rated as moderate. None of these 3 events was a drug related-TEAE. 116 
The 20 drug-related-TEAEs were: cannula site pain (n=2), increased alanine 117 
aminotransferase (n=2), dizziness (n=2), nausea (n=2), thrombophlebitis (n=2), headache 118 
(n=2; i.e., 2 occurrences in one volunteer), palpitations (n=2; 2 occurrences in one volunteer), 119 
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diarrhoea (n=1), discoloured stools (n=1), dissociation (n=1), elevated creatinine kinase (n=1), 120 
rash (n=1), and urine odour abnormal (n=1). 121 
 122 
Pharmacokinetics of Cefepime and Enmetazobactam 123 
 The plasma and ELF pharmacokinetics are shown in Figure 1.  The shape of the ELF PK 124 
profile was comparable to the shape of the plasma concentration time profile for both 125 
cefepime and enmetazobactam.  Concentrations of both cefepime and enmetazobactam 126 
were detectable in plasma for 24 hours after the last administration of drug (i.e., in the 127 
window 64-88 hours post study initiation).  There was no sampling of ELF after 72 hours 128 
(i.e., 8 hours after the final administration of drug). 129 
 130 
Population Pharmacokinetic Modeling  131 
 The fit of a three-compartmental population PK model (representing central, 132 
peripheral and ELF compartments) to the total drug concentration-time data was acceptable 133 
for both drugs in plasma and ELF.  The observed-predicted plots after the Bayesian step and 134 
using the median parameter estimates are shown in Figure 2.  For each drug and output, a 135 
linear regression of observed-predicted values had an intercept and slope that approximated 136 
0 and 1, respectively.  The coefficient of determination for plasma and ELF was an r2 of >97% 137 
for both drugs, and outputs there were acceptable measures of bias and imprecision.   138 
Measures of central tendency for each parameter and their estimated dispersions are 139 
summarized in Table 2.  The full covariance matrix is supplied in supplementary data (Table 140 
S1).  The AUC64-88 (i.e., AUCss determined on day 5 of dosing) in both plasma and ELF was 141 
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calculated from the Bayesian posterior estimates from each volunteer, which were estimated 142 
in Pmetrics using the trapezoidal rule.  The mean ± standard deviation percentage 143 
partitioning of both cefepime and enmetazobactam between plasma and ELF (i.e., AUC64-88 144 
plasma: AUC64-88 ELF) was 60.59 ± 28.62 and 53.03 ± 21.05 %, respectively.  These estimates 145 
were based on measured total drug concentrations in plasma and ELF.   146 
 147 
Assessment of Model Performance 148 
 A visual predictive check showed the majority of observations were contained within 149 
the 5th and 95th centiles of the simulated population that was constructed based on the 150 
healthy volunteers receiving the same regimen as had been used for the volunteers 151 
(i.e., cefepime/ enmetazobactam of 2g/1g q8h i.v. infused over a 2-hour period), suggesting 152 
that the simulation recapitulated the starting population (Figure 3).  The full covariance 153 
matrix was used for the Monte Carlo simulations to account for any potential covariance 154 
between the PK of cefepime and enmetazobactam. 155 
 156 
Relationship Between Drug Exposure in Plasma and ELF 157 
An assessment for the extent of correlation between measures of drug exposure for 158 
cefepime and enmetazobactam in plasma and ELF was performed (Figure 4).  Plasma AUC 159 
does not correlate in a statistically significant manner with ELF AUC in human volunteers. This 160 
could be due to the relatively low number of observations.  In contrast, however, the 161 
estimates for plasma exposure for cefepime and enmetazobactam were strongly correlated 162 
(r=0.642, p<0.01, n=19) and this relationship was even stronger for ELF (r=0.916, p<0.001, 163 
n=19), suggesting that the two test items may have similar pharmacokinetic properties. 164 
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 165 
Probability of Target Attainment 166 
 A Monte Carlo simulation was performed using the regimen that has been recently 167 
studied in a Phase III clinical trial for patients with cUTI and that is proposed for cefepime for 168 
use in nosocomial pneumonia (i.e., cefepime/ enmetazobactam 2g/0.5 g q8h i.v. infused over 169 
a 2-hour period).  The ELF pharmacodynamic targets from a murine model of pneumonia 170 
were used for these calculations that induced a ≥2 log drop (13). These were 20% fT>MIC for 171 
cefepime in ELF, and 20% fT>2 mg/L in ELF for enmetazobactam. The joint probability of 172 
target attainment in ELF was near 100% for isolates with an MIC ≤ 4 mg/L.  The was a 173 
probability of joint target attainment (PTA) of 94.4% and 78.1% for an MIC of 8 mg/L and 16 174 
mg/L, respectively.  Using a 90% joint PTA as an endpoint provided a pharmacodynamic 175 
rationale for setting breakpoint of susceptible 8 mg/L and resistant >8 mg/L.   176 
 177 
  178 
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DISCUSSION 179 
 This study provides one of the key pieces underpinning evidence for the potential role 180 
of cefepime-enmetazobactam for patients with nosocomial pneumonia.  There is a strong 181 
preclinical rationale from neutropenic murine models of thigh infection and pneumonia for 182 
the clinical efficacy of cefepime-enmetazobactam.  The EMA has indicated that new β-183 
lactamase inhibitors, when combined with approved β-lactam antibiotics, can be potentially 184 
approved for use in nosocomial pneumonia based on demonstrated clinical efficacy, a PK-PD 185 
rationale and evidence of adequate partitioning into the epithelial lining fluid in volunteers.  186 
The current study addresses the latter. 187 
 Both cefepime and enmetazobactam partition into epithelial lining fluid in a similar 188 
way as estimated according to total drug AUCplasma: AUCELF, and a visual inspection of the 189 
concentration-time profile of both agents.  This significantly simplifies the selection of 190 
candidate regimens for pneumonia, especially for agents that exhibit time-dependent 191 
pharmacodynamics where both agents must be present at the effect site to derive efficacy—192 
there is nothing to be gained by having high concentrations of the ß-lactamase inhibitor 193 
when there is no cefepime to protect.  Similarly, if cefepime is not protected by a ß-194 
lactamase inhibitor it is susceptible to hydrolysis by ß-lactamases.  The schedule of drug 195 
administration used in this study and the Monte Carlo simulations suggest the proposed 196 
regimen for pneumonia (i.e., cefepime/ enmetazobactam 2g/0.5g i.v. q8h infused over 2-197 
hours) achieves drug exposure targets that result in orders of logarithmic killing in well-198 
characterized murine models of pneumonia across a wide range of MICs. 199 
 The importance of considering the full covariance matrix by fitting the PKs from both 200 
agents simultaneously is highlighted by the extraordinarily high degree of correlation 201 
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between AUC in plasma and ELF for both agents.  The use of a full covariance matrix enables 202 
the pharmacokinetic extremes to be captured and the implications for attainment of desired 203 
drug exposures explored.  Covariance that results in either concordant or discordant drug 204 
exposure may be missed if the PKs are considered as independent events—they clearly are 205 
not.  The underlying biological reason for the correlation is uncertain, but perhaps suggests 206 
that both agents are actively distributed into the ELF.  Whether this is true requires further 207 
study.  There is still little information on the active processes that may be responsible for 208 
movement of drug from plasma to ELF and even less on the impact of infection and 209 
inflammation on these mechanisms.   210 
 The risks of misidentification of an optimal regimen of cefepime-enmetazobactam for 211 
nosocomial pneumonia is relatively low but deserve further discussion.  First, the preclinical 212 
murine targets that have been used are based on those that results in ≥2 logs of kill relative 213 
to stasis in the mouse.  This exceeds the 1-log kill targets achieved in experiments that 214 
determined the targets for ceftazidime-avibactam and ceftolozane-tazobactam (14, 15).  215 
These preclinical murine targets were determined using murine PK with an underlying 216 
assumption that the conversion of pharmacodynamic index corrects for discordant PK 217 
profiles in mice and humans.  At the extremes of pharmacokinetics this assumption may 218 
break down. Secondly, this study used healthy volunteers rather than patients.  Partitioning 219 
of cefepime into the lung of critically ill patients has been previously described (16, 17).  The 220 
point estimates for the PK parameters may be different from patients and the patterns of 221 
drug partitioning may also be different (18).  Almost certainly there will be less variability.  222 
We did not artificially inflate the variance in the simulations, but this is possible.  Higher CV% 223 
for clearance and volume in patients compared with volunteers generally results in a 224 
proportional change in the CV% of drug exposure and generally costs 1-2 MIC dilutions in 225 
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coverage.  Hence the pharmacodynamic breakpoint (i.e., the MIC at which the probability of 226 
target attainment is >90%) may fall from 8 mg/L to 4 mg/L.  Thirdly, there was no assessment 227 
in this study or that considered the emergence of resistance, which may be an issue in 228 
pneumonia where the bacterial burden typically exceeds the mutational frequency of 229 
resistance.  Finally, the dosages used in the healthy volunteer study and those proposed for 230 
use in nosocomial pneumonia are different.  An assumption has been made that the 231 
pharmacokinetics in ELF is linear, whilst the linearity has been confirmed for 232 
pharmacokinetics in plasma.  Despite these limitations, this study provides a solid 233 
pharmacodynamic rationale to consider the use of cefepime-enmetazobactam 2g/0.5g q8h 234 
i.v. for nosocomial pneumonia.   235 





 This study was approved by the North West-Greater Manchester Centre Research 240 
Ethics Committee (17/NW/0171).  A total of 20 healthy volunteers were enrolled at the Royal 241 
Liverpool Hospital Clinical Research Unit, which is a Medicines and Healthcare Regulatory 242 
Agency (MHRA) accredited Phase I unit.   243 
Volunteers from the safety analysis set were males (n=9, 45%) and females (n=11, 244 
55%) aged between 19 and 64 years, with a mean (SD) age of 32.8 (15.2) years (Table 1).  245 
Among them, 12 (60%) were never-smokers or had never used nicotine containing products 246 
and 2 volunteers (10%) never drank alcoholised beverages.  Volunteers had a body mass 247 
index (BMI) that ranged between 21 and 32 kg/m² (median: 25.3 kg/m²).  They had a prior 248 
history of skin or cutaneous disorders (50%), surgical or medical history (40%), psychiatric 249 
disorders (35%), infections or infestations (30%).  The most frequently reported prior 250 
medications belonged to the following Anatomical Therapeutic Chemical (ATC) classes: sex 251 
hormones and modulators of the genital system (25%), analgesics (20%), other 252 
gynaecological drugs (15%), and vitamins (10%). 253 
One volunteer could not tolerate bronchoscopy and was removed from the study.  254 
Two cohorts were used with an interim analysis performed after n= 10 volunteers to ensure 255 




Cefepime (Bristol-Myers Squibb, München) powder was stored at room temperature 259 
and was reconstituted with 20 mL saline in a 2 g-containing vial.  Further dilutions were made 260 
in saline.  Enmetazobactam powder was stored at -20°C and was reconstituted with 5 mL 261 
saline in a 500 mg-containing vial. Further dilutions were made in saline.  All volunteers 262 
received 2 grams of cefepime infused IV over 2 hours and 1 gram of enmetazobactam 263 
infused over 2 hours.  Dose formulations were stored at 4oC for the length of the study (no 264 
longer than 24 hours).  The regimen that was chosen for the current study occurred when 265 
there was debate about the most appropriate dose of enmetazobactam for serious infections 266 
(i.e., 0.5 g q8h versus 1 g q8h i.v.).  Ultimately, a lower dose (i.e., 0.5 g q8h i.v.) was chosen 267 
for the Phase III study 268 
 269 
Pharmacokinetic Sampling 270 
Both cefepime and enmetazobactam were administered q8h i.v.  A single fixed 271 
regimen of 2 g cefepime and 1 g enmetazobactam was simultaneously administered on a q8h 272 
schedule by 2-hour infusion with sampling after the 9th dosage—i.e., from 64 hours post 273 
study initiation and administration of the first dose.  Plasma samples were obtained at 65, 66, 274 
66.5, 67, 68, 70, 72, 76, 80, and 88 hours post dosing (i.e., 1, 2, 2.5, 3, 4, 6, 8, 16- and 24-275 
hours post dose) in each volunteer.  A single bronchoalveolar lavage fluid (BAL) supernatant 276 
sample was obtained per volunteer at 66, 68, 70, or 72 hours (i.e., 2, 4, 6, 8 hours post dose) 277 
post study initiation.  The dilution of ELF was corrected using the ratio of urea concentrations 278 
in plasma and the lavage fluid.  The PK sampling period lasted from the time of last episode 279 
of drug administration to the end of study, which was 64-88 hours, respectively.  280 
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Blood samples (approximately 1 mL) were collected from all individual test volunteers 281 
for quantitation of cefepime or enmetazobactam plasma concentrations and subsequent 282 
population PK analysis.  Whole blood was collected by venipuncture into heparinized 283 
syringes.  Whole blood was then placed into Eppendorf tubes, centrifuged and the plasma 284 
supernatant was removed.  Plasma was stored at -80°C until bioanalysis (cefepime or 285 
enmetazobactam plasma concentration analysis) was performed.  Both drugs were 286 
demonstrated to be stable in plasma stored at -80°C for at least 6-months. 287 
 288 
Bronchoscopy 289 
Bronchoscopy with bronchoalveolar lavage was performed once for each volunteer 290 
and was planned at one of 4 predefined time-points within the 9th dosing interval (time 64-291 
72 hours post study initiation).  The target times were 2 hours, 4 hours, 6 hours, and 8 hours 292 
after the final dosage at 64 hours post treatment initiation. Five volunteers were studied at 293 
each BAL time point (although one volunteer could not tolerate bronchoscopy).   294 
The exact time point corresponding to saline installation and aspiration was recorded.  295 
Volunteers fasted for a minimum of 4 hours prior to bronchoscopy.  Midazolam (i.v.) was 296 
used to achieve the appropriate level of sedation to enable bronchoscopy.  Lignocaine spray 297 
and/or jelly was applied to the oropharynx and nasal passageway, respectively.  Further 298 
anaesthesia of the bronchi and vocal cords and was achieved with 1% and 2% lignocaine, 299 
respectively.  300 
Four aliquots of 50 mL of warmed sterile normal saline (0.9% w/v) were instilled into 301 
the right middle lobe.  After each aliquot, gentle suction was used to aspirate dwelled fluid 302 
and placed on ice.  All BAL aspirates were pooled, and the total volume recorded.  The pooled 303 
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sample was centrifuged at 400 x g for 5 minutes and the supernatant removed.  Two 3 mL 304 
aliquots of supernatant were placed in separate tubes for bioanalysis of cefepime and 305 
enmetazobactam along with estimation of urea concentrations. All samples were frozen and 306 
stored at -70°C.  Measured ELF concentrations of cefepime and enmetazobactam were 307 
corrected for dilution induced by BAL using the ratio of urea concentrations in plasma and 308 
BAL.  This dilution factor was used to “correct” the measured concentrations of cefepime and 309 
enmetazobactam. 310 
Measurement of Cefepime and Enmetazobactam by LC-MS/MS in Human Plasma  311 
Cefepime was extracted from 25 µL of human plasma by protein precipitation using 312 
acetonitrile containing 13C2H3-cefepime as isotopic labelled internal standard and the MRM 313 
transition values for cefepime and the internal standard were m/z 481→125 and m/z 314 
485→125, respectively.  Enmetazobactam was extracted from 20 µL of human plasma by 315 
protein precipitation using acetonitrile containing an isotopically labelled internal standard 316 
([2H3]- enmetazobactam), the MRM transition values were m/z 315→84 for enmetazobactam 317 
and m/z 318→87 for the internal standard.  318 
Concentrations of cefepime and enmetazobactam in human plasma were measured 319 
using a Waters UPLC system coupled with an API4000 in tandem mass spectrometry mode 320 
(LC-MS/MS).  The chromatography was performed for cefepime using gradient elution on a 321 
BETASIL Phenyl-Hexyl (50*2.1 mm, 3.0 µm; Thermo) and for enmetazobactam, isocratic 322 
elution was achieved using an Atlantis HILIC column (50*2.1, 3 m; Waters).  The dynamic 323 
range for cefepime and enmetazobactam was 0.5-500 mg/L and 0.05-50 mg/L, respectively.  324 
The coefficient of determination for a linear regression of the standard curve was >0.99 for 325 
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both analytes.  The inter-run precision was 8.8% and 3.5% for cefepime and 326 
enmetazobactam, respectively. 327 
 328 
Measurement of Cefepime and Enmetazobactam by LC-MS/MS in Human ELF  329 
Concentrations of cefepime and enmetazobactam in human BAL were measured 330 
using a Waters I-Class UPLC system coupled with a Xevo TQ-S in tandem mass spectrometry 331 
mode (LC-MS/MS).  For both analytes, the chromatography was performed in isocratic 332 
elution on a BEH HILIC (50*2.1 mm, 1.7 µm; Waters) and PBS containing 1% BSA was used as 333 
a surrogate matrix for the preparation of calibration standard and quality control samples. 334 
The compounds were extracted from 20 µL of samples by protein crash using acetonitrile 335 
containing the respective labelled internal standard.  The MRM transition values were m/z 336 
481→125 and m/z 485→125 for cefepime and its internal standard ([13C2H3]-cefepime), 337 
respectively, and m/z 315→84 for enmetazobactam and m/z 318→87 for its internal 338 
standard ([2H3]-enmetazobactam).  The dynamic range for both agents was 0.01-10 mg/L.  339 
The coefficient of determination for a linear regression of the standard curve was >0.99 for 340 
both analytes.  The inter-run precision was 1.2% and 5.9% for cefepime and 341 
enmetazobactam, respectively. 342 
  343 
 344 
Measurement of Urea by LC-MS/MS 345 
Urea concentrations were measured in human plasma and human epithelial lining 346 
fluid following modification of a previously described method (19).  A Waters I-Class UPLC 347 
system coupled with a Xevo TQ-S in tandem mass spectrometry mode (LC-MS/MS) was used.  348 
In both matrices, the chromatography was performed in isocratic elution on a BEH HSS T3 349 
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(50*2.1 mm, 1.8 µm; Waters) and calibration curve and quality control samples were 350 
prepared in the respective matrix.  A protein crash was achieved with acetonitrile followed by 351 
a derivatization with camphanic chloride.  [13C15N2]-urea was used as the internal standard. 352 
The MRM transition values were m/z 241→109 and m/z 244→109 for urea and the internal 353 
standard, respectively.  The dynamic range was 5-5000 mg/L and 0.5-50 for human plasma 354 
µg/mL and BAL, respectively.  The coefficient of determination for a linear regression of the 355 
standard curve was >0.99 in both matrices.  The inter-run precision was 2.5% and 4.8% in 356 
plasma and ELF, respectively. 357 
 358 
Population PK Modelling 359 
The PK data from cefepime and enmetazobactam in plasma and ELF were co-modeled 360 
in Pmetrics (20) to identify any potential covariance for the PKs of the two agents.  There was 361 
no implicit assumption of a PK interaction, but the co-modelling enabled possible covariances 362 
between the agents to be captured and be available for subsequent Monte Carlo simulation.  363 
Total drug concentrations were modelled without correction for protein binding.  The 364 
estimated protein binding for enmetazobactam is 0% in human and mouse plasma (21).  365 
Similarly, the estimated protein binding for cefepime is 20 and 0% in human and mouse 366 
plasma, respectively (22, 23).  For measurements beneath the limit of quantification in 367 
plasma a value half-way between zero and the lower limit of quantification were used 368 
(i.e., 0.5 and 0.025 mg/L for cefepime and enmetazobactam, respectively). 369 
 370 
The following structural model was fitted to the total drug concentrations for both cefepime 371 
and enmetazobactam in plasma and ELF: 372 
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 373 
For cefepime: 374 
XP(1)=R(1)-(SCLcef/Vcef)*X(1)-K12*X(1)+K21*X(2)-K13*X(1)+K31*X(3)  Equation 1 375 
XP(2)=K12*X(1)-K21*X(2)        Equation 2 376 
XP(3)=K13*X(1)-K31*X(3)        Equation 3 377 
 378 
For enmetazobactam: 379 
XP(4)=R(2)-(SCLenm/Venm)*X(4)-K45*X(4)+K54*X(5)-K46*X(4)+K64*X(6)  Equation 4 380 
XP(5)=K45*X(4)-K54*X(5)        Equation 5 381 
XP(6)=K46*X(4)-K64*X(6)        Equation 6 382 
 383 
Equation 1, 2 and 3 describe the rate of change of the mass of cefepime in the central, 384 
peripheral and ELF compartments, respectively.  Similarly, Equation 4, 5, and 6 describe the 385 
rate of change of the mass of enmetazobactam in the central, peripheral and ELF 386 
compartments, respectively.  R(1) and R(2) is the infusion of cefepime and enmetazobactam 387 
into the bloodstream (central compartment), respectively.  SCLcef and SCLenm is the first-388 
order clearance of cefepime and enmetazobactam from the central compartment, 389 
respectively; Vcef and Venm is the volume of the central compartment for cefepime and 390 
enmetazobactam, respectively; K with the appropriate subscript represent the first order 391 
intercompartmental rate constants.  XP(1), XP(2) and XP(3) represent the rate of change of 392 
cefepime (mass; mg) in compartments 1, 2 and 3, which represent the central, peripheral 393 
and ELF compartments, respectively.  XP(4), XP(5) and XP(6) represent the rate of change of 394 
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enmetazobactam (mass; mg) in compartments 4, 5 and 6 , which represent the central, 395 
peripheral and ELF compartments, respectively. 396 
There were 4 output equations to describe the concentrations in plasma and ELF of cefepime 397 
(equations 1 and 2, respectively) and for enmetazobactam in plasma and ELF (equations 3 398 
and 4 respectively). 399 
 400 
Output Equations 401 
Y(1) =X(1)/Vcef        Equation 7 402 
Y(2)=X(3)/Vcef_elf        Equation 8 403 
Y(3)=X(4)/Venm        Equation 9 404 
Y(4)=X(6)/Venm_elf        Equation 10 405 
 406 
The output equations contained two additional parameters that were estimated that were 407 
not contained within the ordinary differential equations.  Vcef_elf and Venm_elf are the 408 
volume of the ELF compartment for cefepime and enmetazobactam, respectively.  The 409 
observed data were weighted by the estimated assay variance in plasma and ELF for both 410 
cefepime and enmetazobactam.  Given the complexity of the base structural model, the 411 
number of primary parameters to be estimated and the relatively small sample size, covariate 412 






Bridging and Monte Carlo Simulation 418 
 Monte Carlo simulations were performed with Pmetrics (20).  The full covariance 419 
matrix (Supplementary Table 1) was used for both cefepime and enmetazobactam to enable 420 
PK parameters that may co-vary to do so.  The candidate clinical regimen for nosocomial 421 
pneumonia that was explored in the simulations was cefepime/ enmetazobactam 2g/ 0.5g.  A 422 
total of 1000 simulated patients were generated.  Assessments for target attainment were 423 
performed between 64 and 72 hours post start of therapy.  Targets for success were set for 424 
cefepime and enmetazobactam using free drug at fT>MIC in ELF of 20% and at fT>2 mg/L in 425 
ELF of 20%, respectively, which was based on a recently published murine model of 426 
pneumonia that defined dual pharmacodynamic targets in ELF (13).  This drug exposure 427 
results in ≥2 log decline in bacterial burden in the murine lung relative to stasis (13).  428 
Measured drug in ELF was assumed to be 100% free (i.e., there was no protein binding).  The 429 
requirement to simultaneously achieve both targets to define success was required because 430 
enmetazobactam has no intrinsic activity and no antibacterial activity in the absence of 431 
cefepime.  The rate of success was assessed across a range of MICs (0.125-16 mg/L).  The 432 
distribution of those MICs for cefepime-enmetazobactam against 102 ESBL-producing 433 
Klebsiella pneumoniae obtained from a study of Morrissey et al (3) was used.   434 
 435 
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Demographic Mean Standard 
Deviation 
Sex Male 45% - 
Age 32.8 15.16 
Weight 77.18 11.60 
Height (cm) 173.85 8.31 
Body Mass Index 25.49 3.32 
 546 
Table 1. Demographic details of the 20 volunteers included in this study.  547 
  548 
 28 
 549 
Table 2. 550 
 551 
Parametera(Units) Mean Median SD 
 
SCLcef (L/h) 7.969 7.116 2.190 
Vcef (L) 5.414 5.065 2.692 
K12 (h
-1) 9.645 8.856 6.001 
K21 (h
-1) 7.305 5.105 6.498 
K13 (h
-1) 12.444 9.364 6.049 
K31 (h
-1) 15.732 15.277 7.577 
SCLenm (L/h) 7.822 7.670 1.335 
Venm (L) 4.422 4.101 2.949 
K45 (h
-1) 11.577 10.765 8.429 
K54 (h
-1) 7.058 4.028 8.118 
K46 (h
-1) 16.349 15.958 8.350 
K64 (h
-1) 14.684 16.862 8.673 
Vcef_elf (L) 9.915 6.469 7.441 
Venm_elf (L) 10.148 7.537 6.301 
 552 
aParameter:  SCLcef (liters/h) is the first-order clearance of cefepime from the central 553 
compartment; Vcef (liters) is the volume of the central compartment for cefepime; K12, K21, 554 
K13, K31 are the first-order intercompartmental rate constants, and Vcef_elf is the volume of 555 
the epithelial lining fluid for cefepime.  Similarly, SCLenm is the first-order clearance of 556 
enmetazobactam from the central compartment; Venm is the volume of the central 557 
compartment for enmetazobactam; K45, K54, K46, K64 are the first-order 558 
intercompartmental rate constants, and Venm_elf is the volume of the epithelial lining fluid 559 





Figure 1. Raw pharmacokinetic data from the 19 volunteers for cefepime and 564 
enmetazobactam.  Each solid black circle is a datapoint from plasma or ELF.  Each volunteer 565 
contributes multiple plasma points that are connected by a solid black line and a single ELF 566 
estimate. 567 




Figure 2. Observed-predicted plots after the Bayesian step for cefepime in plasma and 571 
epithelial lining fluid (ELF) in Panels A and B, respectively; and enmetazobactam in plasma 572 
and epithelial lining fluid (ELF) in Panels C and D, respectively.  The mean parameter values 573 
were used to calculate the Bayesian estimates for each volunteer.  The solid line is the linear 574 
regression and the broken line is the line of identity (i.e., observed=predicted).  For Panel A: 575 
Observed=0.29+1.03*Predicted; r2=0.97; for Panel B: Observed=-0.002+Predicted; r2=1.00; 576 
for Panel C: Observed=0.156+0.997*Predicted; r2=0.99; and for Panel D: Observed=-577 










Figure 3. Visual Predictive Check of the fit of the population model to the data obtained from 587 
cefepime in plasma and ELF (Panels A and B, respectively) and enmetazobactam in plasma 588 
and ELF (Panels C and D, respectively).  The open blue circles are the datapoints from plasma 589 
and ELF.  The three grey lines in each plot represent the 5th, 50th and 95th centile and the 590 
shaded areas of the centiles represent the 95% confidence bound around those estimates.  591 




Figure 4. The correlation between area under the concentration-time curve in plasma and 595 
epithelial lining fluid (ELF) for cefepime and enmetazobactam.  Panel A and B: there is not a 596 
statistically significant relationship between AUC in plasma and AUC in ELF for either 597 
cefepime or enmetazobactam.  In contrast, there was a strong correlation between the AUC 598 
in plasma for cefepime and enmetazobactam (Panel C) and in ELF (Panel D).  599 
 600 
 601 






Figure 5. The probability of target attainment in ELF (solid circles) plotted with the 607 
distribution of minimum inhibitory concentration (MIC) values for cefepime-608 
enmetazobactam against 102 ESBL-producing Klebsiella pneumoniae represented by solid 609 
squares.  The pharmacodynamic targets used to define success were determined from a 610 
preclinical murine model of pneumonia using a variety of Klebsiella pneumoniae strains as the 611 
challenge organisms. 612 
